David Chang
2019
In 2019, David Chang earned a total compensation of $11.2M as President and Chief Executive Officer at Allogene Therapeutics, a 13% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $363,000 |
|---|---|
| Option Awards | $5,327,140 |
| Salary | $600,000 |
| Stock Awards | $4,651,970 |
| Other | $250,000 |
| Total | $11,192,110 |
Chang received $5.3M in option awards, accounting for 48% of the total pay in 2019.
Chang also received $363K in non-equity incentive plan, $600K in salary, $4.7M in stock awards and $250K in other compensation.
Rankings
In 2019, David Chang's compensation ranked 613th out of 13,971 executives tracked by ExecPay. In other words, Chang earned more than 95.6% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 613 out of 13,971 | 96th |
Division Manufacturing | 218 out of 5,701 | 96th |
Major group Chemicals And Allied Products | 57 out of 2,200 | 97th |
Industry group Drugs | 47 out of 1,886 | 98th |
Industry Biological Products, Except Diagnostic Substances | 8 out of 389 | 98th |
Source: SEC filing on April 23, 2020.
Chang's colleagues
We found three more compensation records of executives who worked with David Chang at Allogene Therapeutics in 2019.
News
Allogene Therapeutics CEO David Chang's 2021 pay jumps 30% to $10M
April 26, 2022
Allogene Therapeutics CEO David Chang's 2020 pay falls 30% to $7.8M
April 22, 2021
Allogene Therapeutics CEO David Chang's 2019 pay slips 13% to $11M
April 23, 2020
Allogene Therapeutics CEO David Chang receives $13M in 2018
April 24, 2019